The long-term efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine in patients with medication overuse: results of the COMPEL study

被引：0
|
作者：
Tepper, S. [1 ]
Wilson, M. -C. [2 ]
Orejudos, A. [3 ]
Adams, A. Manack [3 ]
Blumenfeld, A. [4 ]
机构：
[1] Geisel Sch Med Dartmouth, Hanover, NH USA
[2] Ochsner Hlth Syst, Covington, LA USA
[3] Allergan Plc, Irvine, CA USA
[4] Headache Ctr Southern Calif, Neurol Cente, Carlsbad, CA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O404
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [1] The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients with Medication Overuse: Results of the COMPEL Study
    Tepper, S. J.
    Wilson, M.
    Orejudos, A.
    Adams, Manack A.
    Blumenfeld, A.
    HEADACHE, 2018, 58 : 93 - 94
  • [2] Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
    Blumenfeld, Andrew M.
    Stark, Richard J.
    Freeman, Marshall C.
    Orejudos, Amelia
    Adams, Aubrey Manack
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [3] Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
    Andrew M. Blumenfeld
    Richard J. Stark
    Marshall C. Freeman
    Amelia Orejudos
    Aubrey Manack Adams
    The Journal of Headache and Pain, 2018, 19
  • [4] Long-term safety and efficacy of onabotulinumtoxinA for the prevention of chronic migraine in a South Korean population: COMPEL study
    Kim, Byung-Kun
    Chu, Min Kyung
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    NEUROLOGY ASIA, 2019, 24 (02) : 127 - 137
  • [5] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia C.
    Mirjah, Debbie L.
    Adams, Aubrey Manack
    Brin, Mitchell F.
    DRUG SAFETY, 2019, 42 (08) : 1013 - 1024
  • [6] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Paul K. Winner
    Andrew M. Blumenfeld
    Eric J. Eross
    Amelia C. Orejudos
    Debbie L. Mirjah
    Aubrey Manack Adams
    Mitchell F. Brin
    Drug Safety, 2019, 42 : 1013 - 1024
  • [7] Efficacy, tolerability, and safety of onabotulinumtoxinA treatment for chronic migraine in patients with acute medication overuse: analysis of the PREEMPT and COMPEL trials
    Agosti, R.
    Straube, A.
    Diener, H. C.
    Freeman, M.
    Pascual Gomez, J.
    Seminerio, M.
    Delahaye, L.
    Stark, R. J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [8] Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results From the COMPEL Study
    Blumenfeld, A. M.
    Luo, L.
    Yedigarova, L.
    Lipton, R. B.
    HEADACHE, 2020, 60 : 101 - 101
  • [9] Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study
    Blumenfeld, Andrew
    Luo, Lei
    Yedigarova, Larisa
    Lipton, Richard
    NEUROLOGY, 2020, 94 (15)
  • [10] OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse
    Guerzoni, Simona
    Cainazzo, Maria Michela
    Pini, Luigi Alberto
    JOURNAL OF HEADACHE AND PAIN, 2015, 16
12345